News & Updates

The direct-acting antiviral (DAA) sofosbuvir/velpatasvir (SOF/VEL) was effective and safe for the treatment of chronic hepatitis C virus (HCV) infection in individuals aged 6–18 years, the PANDAA-PED study has shown.

Both the 2-dose and 3-dose vaccination schedules of the four-component meningococcal serogroup B vaccine (4CMenB) appear to provide protection against a panel epidemiologically relevant strains in adolescents and young adults, according to a phase III study presented at ESPID 2023.

The use of sodium-glucose cotransporter 2 (SGLT2) inhibitors is associated with a reduced risk of incident hepatocellular carcinoma (HCC) in patients with coexisting type 2 diabetes mellitus (T2DM) and chronic hepatitis B (CHB), a territory-wide cohort study in Hong Kong has shown.

The dengue vaccine confers substantial protective benefit on children aged 10 to 15 years, reports a study in the Philippines, which was presented at the recent ESPID 2023.

A study from Singapore demonstrated the usefulness of a systematic programme using combined microbiologic, serologic, and genomic criteria to assess possible COVID-19 reinfection cases.

Some children, particularly boys, continue to gain weight even after COVID-19 pandemic lockdown measures have been eased, indicating the challenges in reversing the effects of lockdowns, reveals a study in Argentina. However, sedentary behaviours have decreased while quality of life has improved.

A meta-analysis of randomized trials has revealed that influenza vaccination is effective at preventing all-cause mortality, cardiovascular mortality, major acute cardiovascular events, and acute coronary syndrome (ACS) among patients with coronary artery disease (CAD), particularly in those with ACS.